Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-08-21
2007-08-21
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S134100, C424S143100, C514S825000
Reexamination Certificate
active
09872185
ABSTRACT:
The present invention provides a method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) in an amount effective to inhibit binding of advanced glycation endproducts (AGEs) to RAGE thereby treating inflammation in the subject. The present invention also provides for a method for treating inflammation in a subject which comprises administering to the subject an agent in an amount effective to inhibit the interaction between receptor for advanced glycation endproduct (RAGE) and its ligand thereby treating inflammation in the subject.
REFERENCES:
patent: 5864018 (1999-01-01), Morser et al.
patent: 5998408 (1999-12-01), Baker et al.
patent: 6555340 (2003-04-01), Schmidt et al.
patent: 7081241 (2006-07-01), Schmidt et al.
patent: 2001/0053357 (2001-12-01), Stern et al.
patent: 2003/0059423 (2003-03-01), Stern et al.
patent: WO 00/20621 (2000-04-01), None
Ritthaler et al. (1995), Expression of Receptors for Advance Glycation End Products in Peripheral Occlusive Vascular Disease, Am.J. Path. vol. 146, No. 3, pp. 668-694.
Hofmann et al. RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptide (1999), Cell, vol. 97, pp. 889-901.
Liotta et al. Cancer: Checkpoint for invasion (2000), Nature, vol. 405, pp. 287-288.
Baynes. J. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412. (Exhibit 1).
Behl. C., et al. (1994). Hydrogen Peroxide Mediates Amyloid β Protein Toxicity Cell 77, 817-827. (Exhibit 2).
Vlassara. H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical. biologic, and clinical implications for diabetes and aging. Lab. Invest. 70: 138-151. (Exhibit 3).
Schmidt. A.M., SD Yan. and D. Stern.(1995). The Dark Side of Glucose (News and Views). Nature Medicine 1:1002-1004. (Exhibit 4).
Schmidt, A.M., Vianna.M., Gerlach. M., Brett. J., Ryan. J., Kao. J., Esposito. C., Hegarty. H., Hurley. W., Clauss. M., Wang. F., Pan. Y.C., Tsang. T.C. and Stern. D. (1992). Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface. J.Biol. Chem. 267,14987-14997.(Exhibit 5).
Brett, J, et al., (1993). Survey of the distribution of a newly-characterized receptor for AGEs in tissues.Am. J. Pathol.143:1699-1712. (Exhibit 6).
Hori O., J. Brett. T. Slattery, R. Cao. J.Zhang. J. Chen, M. Nagashima, D. Nitecki, J. Morser, D. Stern. A.M. Schmidt.(1995). The Receptor for Advanced Glycation Endproducts (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J.Biol. Chem. 270:25752-25761. (Exhibit 7).
Schmidt, A-M. et al. (1994). Cellular Receptors for Advanced Glycation Endproducts.Arterioscler. Thromb., 14:1521-1528. (Exhibit 8).
Schmidt. A-M. et al. (1994). Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins.Proc. Natl. Acad. Sci.(USA). 91:8807-8811. (Exhibit 9).
Sell. D., and Monnier, V. (1989). Structure elucidation of a senescene cross-link from human extracellular matrix: implication of pentoses in the aging process.J.Biol. Chem. 10 264. 21597-21602. (Exhibit 10).
Giardino, I. et al. (1994). Nonenzymatic glycosylation in Vitro and in bovine endothelial cells after basic fibroblast growth factor activity. J. Clin. Invest. 94:110-117. (Exhibit 11).
Park. I.., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079, (Exhibit 12).
Wautier, J.-I.., et al. (1996). Interaction of diabetic erythrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction. Circulation Supplement 94(8):4139. (Enxhibit 13).
Wu J. Rogers L. Stern D. Schmidt AM and Chiu DTW.(1997). The soluble receptor for Advanced Glycation Endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. Plastic Surgery Research Council. Abstract #77, p. 43. (Exhibit 14).
Schmidt, A-M. et al. (1994). Cellular receptors for advanced glycation end products.Arterioscler. Thromb., 14:1521-1528. t. 92:2155-2168. (Exhibit 15).
U.S. Appl. No. 60/469,428, filed May 9, 2003, Schmidt et al.
U.S. Appl. No. 10/840,927, filed May 7, 2004, Schmidt et al.
Herold Kevan
Lamster Ira
Schmidt Ann Marie
Stern David M.
Yan Shi Du
Cooper & Dunham LLP
Saoud Christine J.
Seharaseyon Jegatheesan
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Rage-related methods for treating inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rage-related methods for treating inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rage-related methods for treating inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3828188